Douglas Carr
Directeur Financier/CFO chez CENTURY THERAPEUTICS, INC.
Fortune : 852 541 $ au 30/06/2024
Profil
Douglas Carr is currently the Director at Heritage Conservancy.
He also holds the position of Senior Vice President-Finance & Operations at Century Therapeutics, Inc. since 2024 and Vice President-Finance at Novira Therapeutics, Inc. since 2018.
Previously, he worked as the Business Director-Franchise Division at Zocor Ltd., Controller-Pediatric Vaccines Franchise at Merck & Co., Inc., Financial Controller at Omthera Pharmaceuticals, Inc., and Vice President-Finance & Operations at Century Therapeutics, Inc. He obtained his undergraduate degree from Rutgers State University of New Jersey.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/06/2024 | 334 330 ( 0,40% ) | 852 542 $ | 30/06/2024 |
Postes actifs de Douglas Carr
| Sociétés | Poste | Début |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Directeur Financier/CFO | 02/02/2024 |
| Novira Therapeutics, Inc. | Corporate Officer/Principal | 01/10/2018 |
| Heritage Conservancy | Directeur/Membre du Conseil | - |
Anciens postes connus de Douglas Carr
| Sociétés | Poste | Fin |
|---|---|---|
Century Therapeutics, Inc. /Old/
 Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Directeur Financier/CFO | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| Zocor Ltd. | Corporate Officer/Principal | - |
Omthera Pharmaceuticals, Inc.
 Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Comptroller/Controller/Auditor | - |
Formation de Douglas Carr
| Rutgers State University of New Jersey | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| CENTURY THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Health Technology |
| Zocor Ltd. | |
Century Therapeutics, Inc. /Old/
Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
| Novira Therapeutics, Inc. | |
| Heritage Conservancy |
